Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Director N Anthony Coles Sells 25,000 Shares

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Director N Anthony Coles sold 25,000 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $41.18, for a total transaction of $1,029,500.00. Following the completion of the transaction, the director now directly owns 25,928 shares of the company’s stock, valued at $1,067,715.04. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

N Anthony Coles also recently made the following trade(s):

• On Friday, May 10th, N Anthony Coles sold 50,000 shares of Cerevel Therapeutics stock. The stock was sold at an average price of $42.10, for a total value of $2,105,000.00.

Cerevel Therapeutics Trading Down 2.3 %

Shares of Cerevel Therapeutics stock opened at $40.30 on Thursday. The business’s 50 day simple moving average is $41.46 and its 200 day simple moving average is $41.82. The company has a debt-to-equity ratio of 0.60, a current ratio of 10.22 and a quick ratio of 10.22. Cerevel Therapeutics Holdings, Inc. has a 52-week low of $19.59 and a 52-week high of $43.59.

Cerevel Therapeutics (NASDAQ:CERE) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.12). On average, equities research analysts forecast that Cerevel Therapeutics Holdings, Inc. will post -2.59 EPS for the current fiscal year.

Institutional Investors Weigh In On Cerevel Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Graham Capital Management L.P. grew its holdings in shares of Cerevel Therapeutics by 304.6% in the 3rd quarter. Graham Capital Management L.P. now owns 41,850 shares of the biotechnology company’s stock valued at $914,000 after acquiring an additional 31,506 shares in the last quarter. Hudson Bay Capital Management LP acquired a new position in shares of Cerevel Therapeutics during the 3rd quarter worth approximately $1,092,000. Versor Investments LP acquired a new position in shares of Cerevel Therapeutics during the 4th quarter worth approximately $4,607,000. Calamos Advisors LLC bought a new stake in shares of Cerevel Therapeutics during the 4th quarter worth approximately $12,945,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Cerevel Therapeutics by 25.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 649,333 shares of the biotechnology company’s stock valued at $27,532,000 after buying an additional 132,089 shares during the last quarter. 87.73% of the stock is currently owned by institutional investors and hedge funds.

About Cerevel Therapeutics

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.